Ketoprofen for a National Lameness Control Project
The University of Nottingham · East Midlands
Key facts
- Estimated value
- £150,000
- Closing date
- 23 Feb 2017
- Contract starts
- 13 Mar 2017
- Contract ends
- 31 Mar 2020
- Buyer type
- Education
Description
The University of Nottingham wishes to Contract for a single contractor to supply and deliver Ketoprofen for a National Lameness Control Project.
Lameness remains at unacceptably high levels in developed dairy production systems around the world. The disease compromises welfare but also significantly undermining production and negatively impacting on public perceptions of the industry. The lesions of claw horn disruption (principally sole haemorrhage, sole ulcer and white line disease) are the most common causes of lameness on many farms. Despite their prevalence the causes and prevention of these lesions remains relatively poorly understood. As part of a 5 year Research Partnership with the University of Nottingham and collaborators, AHDB Dairy (the levy body for GB dairy farmers, https://dairy.ahdb.org.uk) funded a successful programme of lameness research which ended in May 2016.
A large scale (~600 cows), long term (~3 years), positively controlled randomised clinical trial will be conducted on a commercial dairy farm in Nottinghamshire, starting in the Autumn of 2017. It will be designed and conducted to investigate the impact of targeted additional treatment with NSAID on future lameness risk and productivity. Low, medium and high intervention groups (compared to a no additional treatment positive control group) will receive the anti-inflammatory Ketoprofen associated with some or all of the following events: calving, foot trimming, a treatment for lameness and an elevated mobility score(s). Points of intervention and duration of anti-inflammatory treatment in the three intervention groups will be decided by a project steering group due to be convened in Spring 2017. Measured outcomes will include lifetime lameness events (mobility score and treatment incidence), health and production data (e.g. milk yield, fertility), and changes to distal limb anatomy (assessed by ultrasound examination in standing cows and by CT, MRI and histopathology in culled cows). Multivariable statistical approaches will be used to investigate the associations between outcomes and treatment group as well as other explanatory variables. The potential cost benefit will be calculated for all levels of anti-inflammatory intervention. This exciting project brings together the GB dairy industry levy board, wider stake holders with an interest in lameness control and a collaborative team of lameness researchers with international reputations in their fields. The research team comprises a diverse skill set and has a proven track record of undertaking and analysing this type of study and publishing outcomes in sector leading journals.
Additional information: For the provision of Ketoprofen for a National Lameness Control Project, PROC DMC ITT/834.
A minimum requirement for this Tender is for the supplier to hold a UK License, to sell a Ketoprofen brand product for the treatment of musculoskeletal disease / lameness in cattle, listed by the Veterinary Medicine Directorate.
You are required to return your submission using the University of Nottingham's e-Tendering web site:
https://in-tendhost.co.uk/universityofnottingham/
Bids must be submitted no later than:
12.00 (noon) on Tuesday 28th February 2017
To return using the web site you need to:
LOG IN click on MY TENDERS then VIEW DOCUMENTS
Follow the instructions on this page
All correspondence relating to this project should be made through the e-Tendering web site.
Click on CREATE CORRESPONDENCE once you have logged on to the Web site and follow the instructions.
Should you encounter any problems with using the Web site, contact the In-Tend Help Desk on 0844 272 8810
Contact at the University of Nottingham for this tender is/are:
Procurement contact: Denise China, 0115 8232329
Technical contact: Jonathan Huxley 0115 9516429
Delivery Notes
Delivery will be via Purchase Order on an adhoc basis over a 3 year period
Is a Recurrent Procurement Type? : No
Categories (CPV)
- 33600000 Pharmaceutical products
Similar open tenders
Global Travel, Accommodation and Venue Management Services
Location: North WestBuyer: Government Commercial Agency
Open tenderCloses 8 Dec, 202633 daysValue £36.25bnSource Find a TenderA framework providing comprehensive booking solutions for all UK Public Sector Travel needs, including air, rail, taxis, coaches, car hire, accommodation and venues for meetings, conferences and events, as well as emergency travel and accommodation solutions, including for civilian cohorts under the care of a UK Public
National Generic Pharmaceuticals – Project Revive
Location: LondonBuyer: NHS England
Open tenderCloses 30 Nov, 202625 daysValue £6.86mSource Find a TenderNational Generic Pharmaceuticals – Project Revive DCE/DSW regions – 01/04/27 to 31/01/29 (22 months) DLS/DNE regions – 01/04/27 to 31/01/29 (22 months) DLN/DNW regions – 01/04/27 to 31/01/29 (22 months)
Orthotic Splints & Braces
Location: West MidlandsBuyer: The Shrewsbury and Telford Hospital NHS Trust
Open tenderCloses 13 Nov, 20268 daysValue £60.14kSource Find a TenderOrthotic Splints & Braces - RJAH, SATH , SCT
UKRI-6412 MRC Harwell Self-Steam Generating Autoclave
Location: South WestBuyer: UK Research & Innovation (UKRI)
Open tenderCloses 30 Nov, 202625 daysValue £150.00kSource Find a TenderMRC Harwell is seeking to replace the existing autoclave with the supply, installation and acceptance of a self-steaming generating autoclave
Cleanroom Consumables
Location: West MidlandsBuyer: The Shrewsbury and Telford Hospital NHS Trust
Open tenderCloses 9 Nov, 20264 daysValue £11.91kSource Find a TenderCleanroom Consumables - SATH & SCT
MED0014 - The Supply of Beating Heart Products
Location: United KingdomBuyer: University Hospitals of North Midlands NHS Trust
Open tenderCloses 16 Nov, 202611 daysValue £18.33kSource Find a TenderBeating heart surgery (Off-Pump Coronary Artery Bypass or OPCAB) utilizes specific stabilization equipment rather than a cardiopulmonary bypass machine.